PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Testosterone - Transgender Health - adults

PAD Profile : Testosterone - Transgender Health - adults

Keywords :
gender reassignment, gender re-assignment, gender identity clinics, GICs, gender incongruence, sex change, transgender, hormonal therapy, masculinisation, transsexuals, hormonal treatment, gender dysphoria
Brand Names Include :
Sustanon 250, Nebido, Testogel, Tostran, Testavan

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Gel
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Education material (for healthcare personnel)

Committee Recommendations

Date
Committee Name
Narrative
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Health System Area Prescribing Committee (APC) has agreed that topical testosterone should be prescribed generically, ideally using Drug Tariff descriptions.

06 December 2023
Surrey Heartlands Medicines Optimisation Board (MOB)

After undertaking a review of previous decisions and resources relating to transgender health, the APC agreed an AMBER status for oestrogen, testosterone, cyproterone, finasteride, GnRH & medroxyprogeterone when used in adults. 

Primary care initiation of these drugs is supported by the APC if the prescriber is competent to exercise their share of clinical responsibility and is assured that the shared care protocol provides enough information for them to discharge their responsibilities safely.

A guide to support primary care prescribing for people who access gender identity services was also agreed by the APC. 

The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.

Associated BNF Codes

06. Endocrine System
06.04.02. Male sex hormones and antagonists
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More